How do you manage leptomeningeal carcinomatosis from a metastatic solid tumor?

Do you prefer WBRT, IT chemo or targeted systemic therapy and what is your preference on the sequence of therapies?

Answer from: Radiation Oncologist at Academic Institution

Several factors are usually considered prior to deciding how to manage patients with leptomeningeal carcinomatosis from a metastatic solid tumor. These factors are tumor type, performance status, neurological status, the bulk of CSF disease, the extra-cranial tumor burden as well as the chance of th...

Comments

Radiation Oncologist at Sacred Heart Cancer Center
@Chi Lin What are your thoughts of treating B...

Radiation Oncologist at University of Nebraska Medical Center
Dear @Gerald C. Lowrey, Thanks for your question. ...

Medical Oncologist at Kettering Cancer Center
Dr. @Chi Lin, any experience with leptomeningeal d...

Radiation Oncologist at University of Nebraska Medical Center
If the patient has a good performance status and w...

Answer from: Radiation Oncologist at Academic Institution

This article has a lot of issues.First of all, authors claimed that this was a phase II clinical trial. However, there was no sample size justification. I believe that this was at most a retrospective analysis of prospectively collected data. And they included only 11 breast cancer patients.Second, ...

Please select the option that best describes you:

How do you manage leptomeningeal carcinomatosis from a metastatic solid tumor?

Related Questions